Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 March 2023 | Story Samkelo Fetile | Photo Simba Matema
MoU Latest News
From left to right: Prof Jean Bernard Lekana-Douki, Director General at the CIRMF; Prof Francis Petersen, Rector and Vice-Chancellor of the UFS; and Prof Jean-Fabrice Yala, Scientific and Technical Director at the CIRMF.

The University of the Free State (UFS) recently welcomed senior members from the International Centre for Medical Research in Franceville (CIRMF), Gabon to sign a Memorandum of Understanding (MoU) between the two entities.

CIRMF is a non-profit medical research centre that was established in 1974. Its primary focus is on diagnosing infectious diseases that pose immediate problems in Gabon and the Central African sub-region. The centre is dedicated to improving public health through various initiatives, including the training of Gabonese health executives in doctoral and post-doctoral education.

“The signing of the MoU with CIRMF is a step in the right direction as the UFS continues to strengthen its footprint on the African Continent. This is seminal in driving the university’s internationalisation processes and opening an avenue to expanding research networks, especially in the African continent,” said Bonolo Makhalemele, Coordinator of strategic projects at the Office for International Affairs, UFS.

In the interest of developing broader research collaborations, the CIRMF delegation met with some UFS academics in a series of engagements, particularly in the Health Sciences Faculty and the Natural and Agricultural Sciences Faculty. “The integration of knowledge and practices that emanate from the continent provides opportunities for the co-creation of knowledge that can be shared with the rest of the world,” said Kagiso Ngake, Coordinator for Partnerships, Collaborative Degrees, and Outgoing Mobility at the Office for International Affairs, UFS.

A concrete roadmap was established to formalise the collaborations that resulted from these engagements and will commence as soon as April 2023. “We have laid a solid foundation and are on the way to a strong and rich partnership!” exclaimed Prof Jean Bernard Lekana-Douki, Director General at the CIRMF.

Prof Francis Petersen, Rector, and Vice-Chancellor of the UFS, further highlighted how the newly established partnership with the CIRMF aligns with the mandate of the UFS Vision 130 of expanding the UFS Africa research network.

News Archive

Science is diversifying the uses of traditional medicines
2017-07-17

Description: Dr Motlalepula Matsabisa  Tags: traditional medicines, Indigenous Knowledge Systems, Dr Motlalepula Matsabisa, Malaria, priority disease  

Dr Motlalepula Matsabisa.
Photo: Anja Aucamp

According to the World Health Organisation, a large majority of the African population are making use of traditional medicines for health, socio-cultural, and economic purposes. In Africa, up to 80% of the population uses traditional medicines for primary healthcare.

The Indigenous Knowledge Systems (IKS) was identified as a lead programme under the directorship of Dr Motlalepula Matsabisa. Research undertaken by the IKS Lead Programme focuses on some key priority diseases of the country and region – including malaria, HIV, cancer, and diabetes.
 
Not just a plant or tree

Malaria is a priority disease and is prevalent in rural and poor areas, resulting in many traditional health practitioners claiming to treat and cure the disease. There may well be substance to these claims, since as much as 30% of the most effective current prescription medicines are derived from plants.  For instance, chloroquine, artemisinin for malaria, Metformin for diabetes, Vincristine and Vinblastine for cancer, are plant-derived drugs.  

Dr Matsabisa’s current research is investigating a South African medicinal plant that has been shown to have in vitro antiplasmodial activity, with subsequent isolation and characterisation of novel non-symmetrical sesquiterpene lactone compounds offering antimalarial activity. These novel compounds are now patented in South Africa and worldwide. This research is part of the UFS and South Africa’s strive to contribute to the regional and continental malaria problem. The UFS are thus far the only university that has been granted a permit by the Medicines Control Council to undertake research on cannabis and its potential health benefits.

“All of these projects are aimed
at adding value through the scientific
research of medicinal plants, which
can be used for treating illnesses,
diseases, and ailments.”

Recognition well deservedThrough Dr Matsabisa’s research input and contributions to the development of the pharmacology of traditional medicines, he recently became the first recipient of the International Prof Tuhinadrin Sen Award from the International Society of Ethnopharmacology (ISE) and the Society of Ethnopharmacology in India. ISE recognises outstanding contributions by researchers, scientists, and technologists in the area of medicinal plant research and ethnopharmacology internationally.

More recently, Dr Matsabisa undertook research projects funded by the National Research Foundation, as well as the Department of Science and Technology, on cancer, gangrene, and diabetes. He is also involved in a community project to develop indigenous teas with the community. He says, “All of these projects are aimed at adding value through the scientific research of medicinal plants, which can be used for treating illnesses, diseases, and ailments”.

Dr Matsabisa has worked with many local and international scientists on a number of research endeavours. He is grateful to his colleagues from the Department of Pharmacology in the Faculty of Health Sciences, who are dedicated to science research and the research of traditional medicines. The IKS unit also received immense support from the Directorate of Research Development.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept